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Introduction
Gut associated lymphoid tissue (GALT) is one of the 
major early targets of HIV infection and an important 
site of HIV persistence during successful antiretroviral 
therapy (ART).1,2 From a clinical point of view patients 
may be asymptomatic or suffer from the so-called HIV 
enteropathy, which remains an important cause of acute 
and chronic non infectious diarrhea, affecting an unknown 
albeit significant proportion of HIV-infected individuals.3
Loss of gastrointestinal (GI) mucosal integrity leads 
to microbial translocation (MT) which results in the 
migration of luminal antigens, including microbial prod-
ucts, into the peripheral circulation. As a consequence, 
microbial antigens can directly stimulate the immune sys-
tem and trigger a cascade of events leading to systemic 
immune activation.4 MT is not unique to HIV disease, 
being a well note feature in other conditions, such as 
chronic liver diseases5−8 and inflammatory bowel disease 
(IBD).9 This latter is characterized by a chronic inflamma-
tory status of intestinal mucosa and can present itself in 
two different forms: Crohn’s disease (CD) and ulcerative 
colitis (UC).
Different mechanisms contribute to MT in IBD and in 
HIV infection. In IBD, the disruption of the GI epithe-
lium is associated with an autoimmune process triggered 
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by unknown causes in a genetically predisposed indi-
vidual;10 in HIV infection, the direct effect of HIV on 
enterocytes and the local activation of GALT are involved. 
Irrespective of the cause, the two conditions share some 
characteristics, including increased levels of markers of 
immune activation, inflammation, and MT. In addition, a 
IBD-like serological pattern was reported in 65% of HIV+ 
patients with high blood levels of lipopolysaccharide 
(LPS).11 These observations have induced some authors 
to suggest HIV testing in subjects with IBD.12
Scarce data exist on the prevalence of IBD in HIV+ 
population, although in a large cohort of seropositive indi-
viduals in UK, the prevalence of UC was double than in 
uninfected population,13 and few studies have investigated 
the interplay between IBD and HIV infection in subjects 
fully responding to ART. Studies in small groups or individ-
ual patients with both HIV infection and IBD in the early 
years of ART era reported no worsening of immunological 
conditions, and an apparently more favorable course of IBD 
has been described.14−17 A more recent study confirmed the 
previous findings, describing a reduction in relapse rates in 
immunocompromised subjects with IBD and HIV.18
Here, we report the results of a cross-sectional study 
where we assessed the impact of IBD in HIV+ subjects 
by measuring markers of MT and inflammation in plasma 
and levels of immune activation both in plasma and in cir-
culating CD4+ and CD8+ T cells. In addition, considering 
the presence of B-cell dysfunction both in HIV infection 
and in IBD, B-cell phenotype was analyzed in all patients.
Methods
Subjects
Case records of 1300 HIV+ subjects attending the out-
patient clinic at the Department of Public Health and 
Infectious Diseases (Sapienza University of Rome) were 
reviewed to identify those with concomitant IBD; 9 
patients, all with histologically proven UC, were found 
(9/1300, 0.69%) and were asked to participate in this 
cross-sectional study; 2 of them refused to participate 
(group HIV/UC, n = 7). Nine patients with HIV infection, 
matched for HIV history and demographic characteris-
tics, were enrolled as controls (group HIV). A third group 
(group UC) of subjects included 10 uninfected individ-
uals with UC, recruited from the Department of Clinical 
Medicine (Sapienza University of Rome). The study was 
approved by Ethics Committee of, Sapienza University 
Policlinico Umberto I°, Rome (Ref. 2789, prot. 915/13). 
All subjects gave their written informed consent
Blood sampling and processing
Twenty ml of peripheral blood was drawn from patients. 
EDTA-blood was processed on the same day of phlebot-
omy. Peripheral blood mononuclear cells (PBMC) were 
obtained by Ficoll gradient centrifugation (Lympholyte, 
Cederlane Laboratories, Ontario, Canada) and analyzed 
the same day. Plasma was collected and stored at −80° 
until required for analysis.
MT and enterocytes damage biomarkers
Soluble sCD14 (sCD14, R&D Systems, Minneapolis, 
MN, USA), EndoCAb IgG (EndoCab Human, ELISA 
Hycult biotech, Uden, the Netherlands), and Intestinal 
fatty acid-binding protein (I-FABP, Hycult biotech, Uden, 
the Netherlands) were measured in plasma according to 
the manufacturer’s instructions.
Inflammation and immune activation markers
Commercially available enzyme-linked immunoassorbent 
assay (ELISA) was used for measuring plasma amount 
of high-sensitive C-reactive protein (hs-CRP, eBiosci-
ence, Vienna Austria), IL-6 (R&D Systems, Minneapolis, 
MN, USA), IL-21 (eBioscience, Vienna Austria), and 
TNF-alpha (R&D Systems, Minneapolis, MN, USA). 
All analyses were performed following manufacturer’s 
instructions.
Flow cytometry
Multi-color flow cytometry was performed on 
PBMCs. Fluorescence intensities were measured with 
a FACSCARIA (BD) and analyzed with FACSDiva 
version 6.1.3 (BD Bioscience, San Diego, CA, USA) 
using cutoffs based on isotype antibody staining. T-cell 
subpopulations were determined using the following 
fluorochrome-conjugated antibodies: PerCP-Cy5.5 
anti-CD3, PE-Cy7 anti-CD4, FITC anti-CD8, in com-
bination with Brilliant Violet 421 anti-CD38, V500 
anti- HLA-DR (all purchased from BD Biosciences, 
San Diego, CA, USA).
B-cell subpopulations were determined using the fol-
lowing fluorochrome-conjugated antibodies: PE-Cy7 
anti-CD19, FITC anti-CD10, PerCP-Cy5.5 anti-CD27, 
and APC anti-CD21 in combination with Brilliant Violet 
421 anti-CD38, PE anti-IL21R (all purchased from BD 
Bioscience, San Diego, CA, USA). Dead cells were 
excluded using Fixable Viability Dye eFluor 780 obtained 
from eBioscience (San Diego, CA, USA).
Statistical Methods
Statistical analyses and graphical presentations were done 
using SPSS software, version 21.00 (IBM, Somers, NY, 
USA). Results are given as median, interquartile range 
(IQR), and percentage. Differences between groups were 
evaluated using the χ2 test or Fisher’s exact test when 
appropriate for categorical variables and by Kruskal–
Wallis and Mann–Whitney U-test for quantitative var-
iables. Post hoc analysis for pairwise comparison was 
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performed applying the Dunn–Bonferroni adjustments 
for multiple testing to detect differences between groups. 
Spearman’s correlation coefficient was used to evaluate 
correlations between quantitative variables. Differences 
were considered statistically significant when p < 0.05.
Results
Patient characteristics
A total of 26 individuals were enrolled in this cross-sec-
tional study. Seven patients were HIV positive and 
affected by histologically diagnosed UC (group HIV/
UC), 9 were HIV-infected (group HIV), and 10 were 
HIV uninfected with UC and (group UC). Demographic 
data and disease(s) characteristics are reported in Table 
1. No differences were observed between groups regard-
ing age, sex, hematological, and biochemical parameters. 
Regarding UC localization, 2 of 7 and 5 of 10 patients 
in groups HIV/UC and UC, respectively, had pancolon 
involvement. They were all treated with mesalazine (dose 
ranging between 2.4 and 3.2 g/die); one patient in group 
HIV/UC was receiving a course of corticosteroids because 
of a clinical relapse. Immunovirological profile of HIV-
infected patients was similar; all had been virologically 
suppressed for at least 1 year, and median number of CD4 
cell was 671 /mm3. ART regimens are reported in Table 
1 and are only apparently variable, since all were based 
on a 3 drugs combination, with the same backbone (TDF/
FTC) in the majority (6 of 7) of HIV/UC subjects and in 
all (9 of 9) of HIV control group.
Table 1 Patient demographic and clinical characteristics. Values are expressed as median and interquartile range or per-
centage
HIV/UC HIV UC All P-values
No. of patients 7 9 10 26
Age (yrs) 51 (34.0–64.0) 46.0 (30.0–64.0) 40.0 (32.0–52.0) 43.0 (34.0 – 60.0) 0.424
Sex (male, %) 71.4 77.8 50.0 69.0 0.538
Smoking n (%) 1/7 (14.3) 3/9 (33.3) 1/10 (10.0) 5/26 (19.2)
BMI 24.8 (21.4–30.7) 25 (22.4–28.0) 24 (21.4–31.5) 24.4 (21.7–29.6) 0.993
Hemoglobin (g/dl) 13.7 (12.5–14.7) 14.1 (12.9–15.3) 14.0 (13.1–16.2) 13.9 (12.7–15.3) 0.483
WBC (cells/ml) 7390 (6160–8650) 6000 (5050 –8100) 5840 (4550–7105) 6180 (5170 –7600) 0.231
Lymphocytes (cells/ml) 2300 (2111–2750) 2270 (1625–2500) 1693 (1310–2024) 2127 (1595–2490) 0.083
IDB characteristics
Duration of UC (yrs) 4.0 (3.0 – 7.0) – 6.5 (2.0–10.3) 5.0 (2.5–11.7) 0.883
Disease activity n (%) 1/7(14.3) – 0/10 (0.0) 1/17 (5.9)
Disease location Pan colon = 2 – Pan colon = 5 Pan colon = 7
Recto-sigma = 5 Recto-sigma = 5 Recto-sigma = 10
IBD pharmacotherapy 7/7 mesalazine – 10/10 mesalazine 1.000
HIV characteristics
Time from HIV diagnosis 11.0 (8.0–12.0) 7 (4.5–2) – 10 (5.3–11.7) 0.286
CDC classification (A/B/C) 4/3/0 7/2/0 – 11/5/0 0.377
Route of infection 7/7 sexual 9/9 sexual – 16/16 sexual 1.000
CD4 cell count (/mm3) 672 (511–1025) 671 (513–785) – 671 (520–804) 0.491
ART therapy 2 – TDF, FTC, EFV 9 – TDF, FTC, EFV –
2 – TDF, FTC, RAL
1 – 3TC, ABC, EFV
1 – TDF, FTC, ATV/r
1 – TDF, FTC, DRV/r
Plasma markers of MT, enterocyte damage, 
inflammation, and immune activation
Patients in group HIV had significantly higher levels 
of soluble CD14 (sCD14) (median: 2166 ng/ml, IQR: 
1618–2523, p = 0.007, Figure 1 A) and fatty acid-bind-
ing proteins (I-FABP) (median 906.7 pg/ml IQR: 667.5–
1373.5, p = 0.001 Table 2, Figure 2). A direct, although 
not significant, correlation was found between elevated 
levels of I-FABP and sCD14 levels (r = 0.355, p = 0.076 
Figure 1B) across the total population, both HIV infected 
and uninfected. The humoral immune response to LPS, 
measured by EndoCAb IgG, did not reveal significant 
differences between groups (Table 2). Similarly, high-sen-
sitive C-reactive protein (hs-CRP), TNF-alpha, IL-6, and 
IL-21 plasma levels were low or below detection limits, 
without differences between groups.
T- and B-cell subsets
As expected, HIV-infected patients (groups HIV/UC 
and HIV) had significantly lower percentages of CD3+/
CD4+ (p = 0.002) and higher percentages of CD3+/CD8+ 
(p = 0.001) cells with respect to group UC (Table 3). No 
differences were seen in the three groups in the percentage 
of B cells (data not shown).
Discussion
The main finding of our study, conducted in a population 
of HIV+ subjects successfully treated with ART, is the 
presence of lower plasma levels of sCD14 and I-FABP 
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in those concomitantly affected by clinically stable UC. 
However, results and statistical analysis should be cau-
tiously interpreted because of the small sample size due 
to the rarity of the study condition (UC in HIV-infected 
subjects). Under these premises, we may say that in our 
study, the presence of UC in HIV-infected subjects does 
not result in increased MT and gut mucosal damage.
Indeed, significantly higher plasma levels of sCD14 
were found in group HIV compared both to HIV/UC 
and UC groups. Similarly, levels of I-FABP, a plasma 
marker of enterocyte damage,19 were higher in HIV 
patients respect to UC group. Recent studies have shown 
that I-FABP levels are associated with mortality and are 
inversely correlated with CD4 cell count in treated HIV 
infection,20 and elevated levels of this marker have been 
associated with the severity of disease in UC.21 In addition, 
a relationship has been reported between plasma levels of 
sCD14 and I-FABP and direct measures of gut epithelial 
damage and mucosal apoptosis,22,23 allowing us to sup-
pose that also at the gut mucosal level, the concomitant 
Figure 1 (A) Plasma levels of soluble CD14 (sCD14) in 
patients with concomitant HIV infection and UC (group HIV/
UC) with HIV infection (group HIV) and with UC (group UC). 
(B) Correlations between I-FABP and sCD14 plasma levels 
(r = 0.355, p = 0.076). Groups are indicated with different dot 
shapes: group HIV/UC (circles); group HIV (diamonds); group 
UC: (triangles).
Table 2 Markers of MT, inflammation, and immune activation in plasma of patients. Values are expressed as median and 
interquartile range
Note: Results of pairwise comparison using the Dunn–Bonferroni post hoc approach were as follows:
*I-FABP: group HIV/UC vs. group HIV: p = 0.688; group HIV/UC vs. group UC: p = 0.075; group HIV vs. group UC: p = 0.001.
#sCD14; group HIV/UC vs group HIV: p = 0.005; group HIV/UC vs. group UC: p = 0.176; group HIV vs group UC: p = 0.473.
°Below detection limit (16.7 pg/ml).
Variables HIV/UC HIV UC p-values
No. of patients 7 9 10
I-FABP (pg/ml) 547.6 (384.9–1352.7) 906.7 (667.5–1373.5) 245.8 (194.1–390.2) 0.001*
EndoCAb (GMU/ml) 85.6 (61.4–107.2) 100.4 (40.9–173.6) 75.8 (51.8–96.9) 0.852
sCD14 (ng/ml) 1469 (1348–1607) 2166 (1618–2523) 1663 (1598–1846) 0.007#
hsCRP (mg/ml) 1.34 (0.61–2.87) 0.57 (0.16–1.21) 0.53 (0.25–1.32) 0.258
IL-6 (pg/ml) 1.59 (1.06–6.24) 1.90 (0.62–3.87) 1.22 (0.36–1.40) 0.211
TNF-alpha (pg/ml) bd° bd bd –
IL-21 (pg/ml) 230.6 (0.33–517.9) 370.0 (246.0–400.7) 139.7 (33.0–278.0) 0.125
Figure 2 Plasma levels of intestinal fatty acid-binding 
protein (I-FABP) in patients with concomitant HIV infection 
and UC (group HIV/UC); with HIV infection (group HIV); with 
UC (group UC).
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reviewing more than 1300 case records of HIV-positive 
subjects referred to one of the largest HIV clinical sites 
in Rome, only 0.69% were found to be affected by IBD, 
and all of them had UC. Therefore, enlarging sample size 
would be a rather unfeasible objective. A further limitation 
is that our study is a cross-sectional one collecting data at 
a single time point.
In conclusion, our results show that in a small popu-
lation of ART-treated HIV-infected subjects affected by 
UC and on long-term treatment with mesalazine, MT and 
systemic inflammation are not enhanced, but seem rather 
mitigated. These data, although scarcely generalizable, 
provide a rationale basis for new randomized clinical trials 
with mesalazine or other gut-specific anti-inflammatory 
drugs, to explore whether they can represent a valid ther-
apeutic approach to control MT in HIV patients.
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